NPM1 Measurable Residual Disease: A Narrative Review.

IF 0.6 4区医学 Q4 HEMATOLOGY

Indian Journal of Hematology and Blood Transfusion Pub Date : 2025-07-01 Epub Date: 2025-01-27 DOI:10.1007/s12288-025-01958-4

Yadav Chitresh, Nathany Shrinidhi, Kumar Nikhil M, Swaminathan Anusha, Panda Rastogi Neha, Verma Kanika, Saini Manish, Verma Hari Stuti, Danewa Arun, Dua Vikas, Bhargava Rahul

{"title":"NPM1 Measurable Residual Disease: A Narrative Review.","authors":"Yadav Chitresh, Nathany Shrinidhi, Kumar Nikhil M, Swaminathan Anusha, Panda Rastogi Neha, Verma Kanika, Saini Manish, Verma Hari Stuti, Danewa Arun, Dua Vikas, Bhargava Rahul","doi":"10.1007/s12288-025-01958-4","DOIUrl":null,"url":null,"abstract":"Acute myeloid leukemia (AML) with mutated NPM1 (Nucleophosmin 1) is a distinct entity in the 5th edition of the World Health Organization (WHO) Classification as well as a favourable risk category in the 2022 European LeukemiaNet (ELN) Recommendations for AML. The development of myriad techniques for detection of NPM1 Measurable Residual Disease (MRD) has led to improved patient outcomes; however, there is no one winner. Each modality has its own nuances and caveats, and hence using a synoptic and integrated approach is recommended to avoid potential false negatives. Therapy guided by genomic MRD especially in decision for timing of transplant has been reported in literature, which has shown benefits of regular longitudinal monitoring of NPM1. This is a narrative review which discusses in detail the testing modalities for NPM1 MRD in AML. Keywords like 'NPM1\", \"MRD\", \"NGS\", were searched in Pubmed, Embase and Scopus and a total of 40 articles were included. Since this is not a systematic review or meta-analysis no inclusion or exclusion criteria were laid and no formal statistics was done. This article was constructed in pursuit of raising awareness for this unmet need, as well as to amalgamate all old and new knowledge in this space. The future is artificial intelligence and machine learning which may pave the way for risk scores.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-025-01958-4.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 3","pages":"453-459"},"PeriodicalIF":0.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267802/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-025-01958-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acute myeloid leukemia (AML) with mutated NPM1 (Nucleophosmin 1) is a distinct entity in the 5th edition of the World Health Organization (WHO) Classification as well as a favourable risk category in the 2022 European LeukemiaNet (ELN) Recommendations for AML. The development of myriad techniques for detection of NPM1 Measurable Residual Disease (MRD) has led to improved patient outcomes; however, there is no one winner. Each modality has its own nuances and caveats, and hence using a synoptic and integrated approach is recommended to avoid potential false negatives. Therapy guided by genomic MRD especially in decision for timing of transplant has been reported in literature, which has shown benefits of regular longitudinal monitoring of NPM1. This is a narrative review which discusses in detail the testing modalities for NPM1 MRD in AML. Keywords like 'NPM1", "MRD", "NGS", were searched in Pubmed, Embase and Scopus and a total of 40 articles were included. Since this is not a systematic review or meta-analysis no inclusion or exclusion criteria were laid and no formal statistics was done. This article was constructed in pursuit of raising awareness for this unmet need, as well as to amalgamate all old and new knowledge in this space. The future is artificial intelligence and machine learning which may pave the way for risk scores.

Supplementary information: The online version contains supplementary material available at 10.1007/s12288-025-01958-4.

查看原文本刊更多论文

可测量的NPM1残留疾病：叙述回顾。

NPM1（核磷蛋白1）突变的急性髓性白血病（AML）是世界卫生组织（WHO）第5版分类中的一个独特实体，也是2022年欧洲白血病网（ELN） AML建议中的一个有利风险类别。用于检测NPM1可测量残留病（MRD）的无数技术的发展已经改善了患者的预后；然而，没有一个赢家。每种形态都有自己的细微差别和注意事项，因此建议使用综合的方法来避免潜在的假阴性。以基因组MRD为指导的治疗，特别是在移植时机的决定方面，已有文献报道，显示了定期对NPM1进行纵向监测的益处。这是一篇叙述性综述，详细讨论了AML中NPM1 MRD的检测方式。在Pubmed、Embase和Scopus中检索关键词“NPM1”、“MRD”、“NGS”，共收录40篇文章。由于这不是一项系统评价或荟萃分析，因此没有制定纳入或排除标准，也没有进行正式统计。本文旨在提高人们对这一未满足需求的认识，并将这一领域的所有新旧知识结合起来。未来是人工智能和机器学习，这可能为风险评分铺平道路。补充资料：在线版本包含补充资料，可在10.1007/s12288-025-01958-4获得。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Hematology and Blood Transfusion HEMATOLOGY-

CiteScore

1.70

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.